Registration opens for first public hearing
The European Medicines Agency (EMA) is inviting citizens to share their experience with valproate – a medicine that treats epilepsy, bipolar disorder and migraine – at its very first public hearing on 26 September 2017 at the Agency’s offices in London.
More information on the following link:
EMA seeks views of public during its safety review of valproate
